dc.contributor.author | Valencia, Pedro M | |
dc.contributor.author | Pridgen, Eric M | |
dc.contributor.author | Perea, Brian | |
dc.contributor.author | Gadde, Suresh | |
dc.contributor.author | Sweeney, Christopher | |
dc.contributor.author | Kantoff, Philip W. | |
dc.contributor.author | Bander, Neil H. | |
dc.contributor.author | Langer, Robert | |
dc.contributor.author | Lippard, Stephen J. | |
dc.contributor.author | Farokhzad, Omid C. | |
dc.contributor.author | Karnik, Rohit | |
dc.contributor.author | Valencia, Pedro M. | |
dc.contributor.author | Pridgen, Eric M. | |
dc.date.accessioned | 2015-02-19T20:33:47Z | |
dc.date.available | 2015-02-19T20:33:47Z | |
dc.date.issued | 2012-10 | |
dc.date.submitted | 2012-06 | |
dc.identifier.issn | 1743-5889 | |
dc.identifier.issn | 1748-6963 | |
dc.identifier.uri | http://hdl.handle.net/1721.1/95422 | |
dc.description.abstract | Aim: Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are: actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. Materials & methods: Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices. Results: I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. Conclusion: The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer. | en_US |
dc.description.sponsorship | Prostate Cancer Foundation (Nanotherapeutics Award) | en_US |
dc.description.sponsorship | MIT-Harvard Center of Cancer Nanotechnology Excellence (U54-CA151884) | en_US |
dc.description.sponsorship | National Science Foundation (U.S.). Graduate Research Fellowship Program | en_US |
dc.description.sponsorship | American Society for Engineering Education. National Defense Science and Engineering Graduate Fellowship | en_US |
dc.language.iso | en_US | |
dc.publisher | Future Medicine | en_US |
dc.relation.isversionof | http://dx.doi.org/10.2217/nnm.12.134 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | en_US |
dc.source | PMC | en_US |
dc.title | Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Valencia, Pedro M, Eric M Pridgen, Brian Perea, Suresh Gadde, Christopher Sweeney, Philip W Kantoff, Neil H Bander, et al. “Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles.” Nanomedicine 8, no. 5 (May 2013): 687–698. | en_US |
dc.contributor.department | MIT-Harvard Center for Cancer Nanotechnology Excellence | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Institute for Medical Engineering & Science | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Chemical Engineering | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Chemistry | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Mechanical Engineering | en_US |
dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
dc.contributor.mitauthor | Valencia, Pedro M. | en_US |
dc.contributor.mitauthor | Pridgen, Eric M. | en_US |
dc.contributor.mitauthor | Langer, Robert | en_US |
dc.contributor.mitauthor | Lippard, Stephen J. | en_US |
dc.contributor.mitauthor | Farokhzad, Omid C. | en_US |
dc.contributor.mitauthor | Karnik, Rohit | en_US |
dc.relation.journal | Nanomedicine | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.orderedauthors | Valencia, Pedro M; Pridgen, Eric M; Perea, Brian; Gadde, Suresh; Sweeney, Christopher; Kantoff, Philip W; Bander, Neil H; Lippard, Stephen J; Langer, Robert; Karnik, Rohit; Farokhzad, Omid C | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-0588-9286 | |
dc.identifier.orcid | https://orcid.org/0000-0002-2693-4982 | |
dc.identifier.orcid | https://orcid.org/0000-0002-2640-3006 | |
dc.identifier.orcid | https://orcid.org/0000-0003-4255-0492 | |
dspace.mitauthor.error | true | |
mit.license | OPEN_ACCESS_POLICY | en_US |
mit.metadata.status | Complete | |